Home Newsfeeds Mizuho Maintains Buy on Haemonetics, Raises Price Target to $100

Mizuho Maintains Buy on Haemonetics, Raises Price Target to $100

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $90 to $100.

byBenzinga Newsdesk

November 8, 2022

1 minute read

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $90 to $100.

Morgan Stanley Maintains Overweight on T-Mobile US, Raises Price Target to $180

By Benzinga Newsdesk

October 31, 9:33 AM

Morgan Stanley analyst Simon Flannery maintains T-Mobile US (NASDAQ:TMUS) with a Overweight and raises the price target from $159 to $180.

TMUS

Wells Fargo Upgrades NOV to Equal-Weight, Raises Price Target to $25

By Benzinga Newsdesk

November 7, 7:13 AM

Wells Fargo analyst Roger Read upgrades NOV (NYSE:NOV) from Underweight to Equal-Weight and raises the price target from $16 to $25.

NOV

Dow Rises 50 Points; American Express Earnings Top Views

By Lisa Levin

July 21, 9:53 AM

U.S. stocks traded higher this morning, with the Dow Jones gaining around 50 points on Friday. Following the market opening Friday, the Dow traded up 0.14% to 35,275.55 while the NASDAQ rose 0.52% to 14,135.92. The S&P 500, also rose, gaining, 0.32% to 4,549.47.

AXP

Here’s How Much You Would Have Made Owning Microchip Technology Stock In The Last 15 Years

By Benzinga Insights

December 5, 1:30 PM

Microchip Technology (NASDAQ:MCHP) has outperformed the market over the past 15 years by 3.84% on an annualized basis…

MCHP

Mizuho Maintains Buy on Haemonetics, Raises Price Target to $100

Related Posts

Morgan Stanley Maintains Overweight on T-Mobile US, Raises Price Target to $180

Wells Fargo Upgrades NOV to Equal-Weight, Raises Price Target to $25

Dow Rises 50 Points; American Express Earnings Top Views

Here’s How Much You Would Have Made Owning Microchip Technology Stock In The Last 15 Years